2 patents
Utility
Dosing Regimen
22 Apr 21
The invention provides for a dosing regimen for human antibodies that bind to human platelet-derived growth factor receptor alpha (PDGFR alpha), preferably olaratumab.
John Robert Baldwin, Ilaria Conti, Damien Michel Cronier, Robert Leslie Ilaria, JR., Zhi Lin Mo
Filed: 6 Nov 20
Utility
Anti-VEGFR2 antibody therapy for hepatocellular carcinoma
7 Sep 20
The invention provides for a human antibody that binds to human vascular endothelial growth factor receptor 2, preferably ramucirumab, for the treatment of hepatocellular carcinoma (HCC) in patients having levels of alpha-fetoprotein (AFP) of 1.5×ULN (Upper Limit of Normal) or greater, and as a predictive method for the treatment of HCC in patients having AFP levels of 1.5×ULN or greater.
Paolo B. Abada, Shao-Chun Chang, Yanzhi Hsu, Ling Yang
Filed: 10 Aug 15
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first